- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03418428
Intestinal Microbiome After Gastrectomy (DiGMA)
Surgical Gastric Cancer Treatment: Influence on Intestinal Microbiome
The gastric barrier plays a major role in the maintanance of the distal intestinal microbiome composition. It has been shown before that the use of gastric acid suppression medication, such as proton pump inhibitors, are associated with distinctive alterations of the intestinal microbiome. Foremost, the invasion of predominantly oral bacteria, like Veillonella and Streptococcus species, were a resurring finding in previous reports.
Gastric cancer treatment includes the total or subtotal resection of the stomach which can influence the gastric acid production. However, the influence by alterations in gastric milieu after this treatment on the composition of the intestinal microbiome is not well studied.
Therefore, the intestinal microbiome of patients after total or subtotal gastrectomy and its influence on intestinal inflammation and gut permeability will be studied.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
-
Vilnius, Litauen
- National Cancer Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- age 18 years and above
- history of radical removal of gastric cancer (Test group and Control group 1) or PPI (Control group 3)
- informed consent
Exclusion Criteria:
- chemotherapy or radiotherapy 12 months prior to inclusion
- gastric stump cancer
- usage of antibiotics, pro- pre or synbiotics, H2-blocker 1 month prior to inclusion
- PPI use (except for Control group 3) 1 month prior to inclusion
- history of radical removal of gastric cancer (Control group 2-3)
- history of gastrointestinal tract resections (other than gastric)
- recurrence of gastric cancer
- current non-gastric malignancies
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Test group
Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
|
Control group 1
Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
|
Control group 2
In-house relatives of Test group and Control group 1 participants
|
Control group 3
Patients with long-term history of proton pump inhibitor usage
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Intestinal microbiome composition
Tidsramme: 5 years after surgery
|
Significant differences in the beta-diversity of the intestinal microbiome between Test group and Control groups
|
5 years after surgery
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Intestinal microbiome composition (II)
Tidsramme: 5 years after surgery
|
Significant differences in the alpha-diversity of the intestinal microbiome between Test group and Control groups
|
5 years after surgery
|
Fecal calprotectin
Tidsramme: 5 years after surgery
|
Significant differences in intestinal inflammation measured by fecal calprotectin between Test group and Control groups
|
5 years after surgery
|
Fecal zonulin
Tidsramme: 5 years after surgery
|
Significant differences in intestinal permeability measured by fecal zonulin between Test group and Control groups
|
5 years after surgery
|
Serum LPS
Tidsramme: 5 years after surgery
|
Significant differences in serum LPS between Test group and Control groups
|
5 years after surgery
|
Serum sCD14
Tidsramme: 5 years after surgery
|
Significant differences in serum sCD14 between Test group and Control groups
|
5 years after surgery
|
Serum LBP
Tidsramme: 5 years after surgery
|
Significant differences in serum LBP between Test group and Control groups
|
5 years after surgery
|
Serum sCD163
Tidsramme: 5 years after surgery
|
Significant differences in serum sCD163 between Test group and Control groups
|
5 years after surgery
|
Serum sMR
Tidsramme: 5 years after surgery
|
Significant differences in serum sMR between Test group and Control groups
|
5 years after surgery
|
Serum CRP
Tidsramme: 5 years after surgery
|
Significant differences in serum CRP between Test group and Control groups
|
5 years after surgery
|
Serum DAO
Tidsramme: 5 years after surgery
|
Significant differences in serum DAO between Test group and Control groups
|
5 years after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DiGMA_2018
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Magekreft
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertical Sleeve Gastrectomy | Magebånd | Bypass, GastricForente stater
-
Medtronic - MITGFullført
-
Wageningen UniversityRijnstate HospitalUkjentRoux-en-Y Gastric BypassNederland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtRoux en Y Gastric BypassForente stater
-
DuomedAktiv, ikke rekrutterendeOvervekt | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgia
-
North Dakota State UniversityNational Institutes of Health (NIH)FullførtRoux en Y Gastric Bypass kirurgiForente stater
-
Olympus Corporation of the AmericasUnity Health TorontoFullført
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtSleeve Gastrectomy | Roux en Y Gastric BypassForente stater
-
Rijnstate HospitalFullførtRoux-en-Y Gastric Bypass | Magetømming | Bariatrisk kirurgiNederland
-
Rijnstate HospitalFullførtBariatrisk kirurgi | Jern absorpsjon | Roux- en -y Gastric BypassNederland